Haleon (NYSE: HLN) updates total voting rights with 8.91B shares
Filing Impact
Filing Sentiment
Form Type
6-K
Rhea-AI Filing Summary
Haleon plc reported its share capital and voting rights as of 30 November 2025. The company has issued a total of 8,952,353,648 ordinary shares of £0.01 each, of which 45,882,158 are held as treasury shares. This leaves 8,906,471,490 ordinary shares with voting rights.
The company states that this voting-rights figure should be used by shareholders and others with notification obligations as the denominator when calculating whether they must disclose their interest in Haleon under the FCA's Disclosure Guidance and Transparency Rules.
Positive
- None.
Negative
- None.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF
1934
For the month of December 2025
Commission File Number: 001-41411
Haleon plc
(Translation
of registrant’s name into English)
Building 5, First Floor, The Heights,
Weybridge, Surrey, KT13 0NY
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F:
|
|
Form
20-F ☒
|
Form
40-F ☐
|
|
EXHIBIT INDEX
|
Exhibit
Number
|
Description
|
|
99.1
|
01
December 2025 - “Total Voting
Rights and Capital”
|
99.1
Haleon plc: Total Voting Rights and Capital
01 December 2025: As
at 30 November 2025 the total number of shares issued by Haleon plc
("Haleon" or the "Company") is 8,952,353,648 ordinary
shares of £0.01 each, of which 45,882,158 are
held as treasury shares.
Therefore, the number of ordinary shares with voting rights
is 8,906,471,490 and
this figure should be used by shareholders (and others with
notification obligations) as the denominator for the calculation by
which they will determine if they are required to notify their
interest in, or a change to their interest in, the Company under
the FCA's Disclosure Guidance and Transparency
Rules.
Notifiable interests in Haleon may be sent to: company.secretary@haleon.com
Amanda Mellor
Company Secretary
About Haleon
Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with
a purpose to deliver better everyday health with humanity. Haleon's
product portfolio spans six major categories - Oral Health,
Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory
Health, Digestive Health and Therapeutic Skin Health and Other. Its
long-standing brands - such as Advil, Centrum, Otrivin,
Panadol, parodontax, Polident, Sensodyne,
Theraflu and Voltaren - are built on trusted science, innovation
and deep human understanding.
For more information, please visit www.haleon.com.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
|
|
HALEON PLC
(Registrant)
|
|
|
Date:
December 01, 2025
|
By:
|
/s/
Amanda Mellor
|
|
|
|
|
Name:
|
Amanda
Mellor
|
|
|
|
Title:
|
Company
Secretary
|
FAQ
What denominator should Haleon (HLN) investors use for FCA disclosure calculations?
Investors should use 8,906,471,490 ordinary shares with voting rights as the denominator for FCA Disclosure Guidance and Transparency Rules calculations.
Who is the company secretary of Haleon plc mentioned in this report?
The company secretary of Haleon plc named in the report is Amanda Mellor.
In which sectors does Haleon (HLN) operate as a consumer health company?
Haleon operates across six categories: Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health and Other.